Oslo, Norway, 9 August 2010 – Algeta ASA (OSE: ALGETA), the focused oncology company,
will announce its second quarter 2010 results on Friday, 13 August 2010. A presentation
to investors, analysts and the press will take place in Oslo at 09:45 CET. Algeta’s
President and CEO Andrew Kay, CTO Thomas Ramdahl and CFO Øystein Soug will present.
The presentation will also be webcast live and can be accessed from
www.algeta.com/webcast http://www.algeta.com/webcast
where questions can be submitted live during the presentation.
The presentation will take place at 09:45 CET at:
Hotel Continental
Stortingsgaten 24/26
0117 Oslo
Norway.
The results report and the presentation will be made available on
www.algeta.com http://www.algeta.com/
in the Investors section from 08:00 CET.
###
For further information, please contact
Andrew Kay, CEO +47 2300 7990 / +47 4840 1360 (mob)
Øystein Soug, CFO
+47 2300 7990 / +47 9065 6525 (mob)
post@algeta.com
International media enquiries: +44 207 638 9571
Mark Swallow/Helena Galilee/David Dible
mark.swallow@citigatedr.co.uk mailto:mark.swallow@citigatedr.co.uk
Citigate Dewe Rogerson
US investor enquiries: +1 646 378 2928
Jessica Lloyd
jlloyd@troutgroup.com mailto:jlloyd@troutgroup.com
The Trout Group
US investor enquiries:
Jessica Lloyd
The Trout Group
+1 646 378 2928
jlloyd@troutgroup.com mailto:jlloyd@troutgroup.com
About Algeta
Algeta is a focused oncology company developing novel targeted therapies for patients
with cancer based on its alpha-pharmaceutical platform.
Algeta’s lead product Alpharadin (based on radium-223) is a first-in-class, highly
targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients
with bone metastases from advanced cancer. Its localized action helps preserve the
surrounding healthy tissue thereby limiting side-effects.
The development of bone metastases represents a serious development for cancer patients
as they are associated with a dramatic decline in patient health and quality of life,
ultimately leading to death. Bone metastases represent a major unmet medical need,
occurring in up to 90% of certain late-stage cancers, e.g. prostate, breast and lung.
Alpharadin is being developed under a development and commercialization agreement with
Bayer Schering Pharma AG, a major pharmaceutical company, and is in a global phase III
clinical trial (ALSYMPCA) to treat bone metastases resulting from castration-resistant
(hormone-refractory) prostate cancer. Alpharadin is also under investigation in phase II
clinical trials as a potential new treatment for bone metastases in endocrine resistant
breast cancer patients.
Algeta also aims to develop a future pipeline of tumor-targeting alpha-pharmaceutical
candidates based on the alpha particle emitter thorium-227, through selective
in-licensing and/or acquiring innovative technologies and tumor-targeting molecules.
The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on
the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will occur in
the future and which, by their nature, will have an impact on results of operations and
the financial condition of Algeta. There are a number of factors that could cause actual
results and developments to differ materially from those expressed or implied by these
forward-looking statements. Theses factors include, among other things, risks associated
with technological development, the risk that research & development will not yield new
products that achieve commercial success, the impact of competition, the ability to
close viable and profitable business deals, the risk of non-approval of patents not yet
granted and difficulties of obtaining relevant governmental approvals for new products.
###
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian
Securities Trading Act)
HUG#1436510
